[1]
|
M. Meittinen, M. Sarlomo-Rikala and J. Lasota, “Gastrointestinal Stromal Tumors,” Annales Chirurgiae et Gynaecologiae Fenniae, Vol. 87, No. 4, 1998, pp. 278-281.
|
[2]
|
S. R. Hamilton and L. A. Aaltonen, “World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Digestive System,” IARC Press, Lyon, 2000.
|
[3]
|
L. G. Kindblom, H. E. Remotti, F. Aldenborg and J. M. Meis-Kindblom, “Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of Cajal,” American Journal of Pathology, Vol. 152, No. 5, 1998, pp. 1259-1269.
|
[4]
|
C. D. Fletcher, J. J. Berman, C. Corless, et al., “Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach,” Human Pathology, Vol, 33, No. 5, 2002, pp. 459-465. doi:10.1053/hupa.2002.123545
|
[5]
|
E. Wardelmann, I. Neidt, E. Bierhoff, et al., “c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather than in the Epitheiloid Cell Variant,” Modern Pathology, Vol. 15, No. 2, 2002, pp. 125-136. doi:10.1038/modpathol.3880504
|
[6]
|
S. Suster, D. Sorace and A. Moran, “Gastrointestinal Stromal Tumours with Prominent Myxoid Matrix. Clinicopathologic, Immunohistochemical and Ultrastructural Study of Nine Cases of a Distinctive Morphologic Variant of Myogenic Stromal Tumor,” American Journal of Surgical Pathology, Vol. 19, No. 1, 1995, pp. 59-70.
doi:10.1097/00000478-199501000-00008
|
[7]
|
S. Sakurai, T. Hasegawa, Y. Sakuma, et al., “Myxoid Epithelioid Gastrointestinal Stromal Tumor (GIST) with Mast Cell Infiltrations: A Subtype of GIST with Mutations of Platelet-Derived Growth Factor Receptor Alpha Gene,” Human Pathology, Vol. 35, No. 10, 2004, pp. 1223-1230. doi:10.1016/j.humpath.2004.07.008
|
[8]
|
A. Rajput, C. Levea, M. Intengan, J. Kane and J. F. Gibbs, “Gastrointestinal Stromal Tumor: Chondro-Myxoid Variant Mimicking Chondrosarcoma,” Sarcoma, Vol. 91, No. 1-2, 2005, pp. 25-28.
doi:10.1080/13577140500043708
|
[9]
|
T. Hasegawa, Y. Matsuno, T. Shimoda, et al., “Gastrointestinal Stromal Tumor: Consistent CD117 Immunostaining for Diagnosis, and Prognostic Classification Based on Tumor Size and MIB-1 Grade,” Human Pathology, Vol. 33, No. 6, 2002, pp. 669-676.
doi:10.1053/hupa.2002.124116
|
[10]
|
M. R. Peterson, Z. Piao, N. Weidner and E. S. Yi, “Strong PDGFRA Positivity Is Seen in GISTs but Not in Other Intrabdominal Mesenchymal Tumors: Immunohistochemical and Mutational Analyses,” Applied Immunohistochemistry & Molecular Morphology, Vol. 14, No, 4, 2006, pp. 390-396. doi:10.1097/01.pai.0000203038.33414.a3
|
[11]
|
M. C. Heinrich, C. L. Corles, A. Duensing, et al., “PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors,” Science, Vol. 299, No. 5607, 2003, pp. 708-710. doi:10.1126/science.1079666
|
[12]
|
S. Hirota, A. Obashi, T. Nishida, et al., “Gain-of-Function Mutations of Platelet-Derived Growth Factor Receptor Alpha Gene in Gastrointestinal Stromal Tumors,” Gastroenterology, Vol. 125, No. 3, 2003, pp. 660-667.
doi:10.1016/S0016-5085(03)01046-1
|
[13]
|
M. C. Heinrich, C. L. Corless, G. D. Demetri, et al., “Kinase Mutations and Imatinib Response in Patients with Metastatic Gastrointestinal Stromal Tumor,” Journal of Clinical Oncology, Vol. 21, No. 23, 2003, pp. 4342- 4349. doi:10.1200/JCO.2003.04.190
|
[14]
|
G. H. Kang, A. Srivastava, Y. E. Kim, et al., “DOG1 and PKC? Are Useful in the Diagnosis of KIT-Negative Gastrointestinal Stromal Tumors,” Modern Pathology, in Press.
|
[15]
|
M. Novelli, S. Rossi, M. Rodriguez-Justo, et al., “DOG1 and CD117 Are the Antibodies of Choice in the Diagnosis of Gastrointestinal Stromal Tumors,” Histopathology, Vol. 57, No. 2, 2010, pp. 259-270.
doi:10.1111/j.1365-2559.2010.03624.x
|
[16]
|
Y. Jiang, L. Ming, A. J. Montero, E. Kimchi, M. Nikfarjam and K. F. Staveley-O’Carroll, “Optimizing Imatinib Mesylate Treatment in Gastrointestinal Stroma Tumors,” Gastrointestinal Cancer Research, Vol. 2, No. 5, 2008, pp. 245-250.
|
[17]
|
Y. Koh, H. Kim, H. Lee, D. Oh, J. Kim, S. Im, et al., “KIT and PDGFRA Mutation Status and Their Immunohistochemical (IHC) Expression Profile of Gastrointestinal Stromal Tumor (GIST) Patients with Imatinib (IMT): Seven-Year Single-Center Experience,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, p. 27.
|
[18]
|
V. B. Shidham, M. Chivukula, D. Gupta, R. N. Rao and R. Komorowski, “Immunohistochemical Comparison of Gastrointestinal Stromal Tumor and Solitary Fibrous Tumor,” Archives of Pathology & Laboratory Medicine, Vol. 126, No. 10, 2002, pp. 1189-1192.
|